Two new drug treatments are making strides in treating neuropathic pain. One drug, Lyrica (pregabalin), has been approved by the European Commission to treat the condition. The approval joins the U.S. Food and Drug Administration's nod for the use of Lyrica in diabetic neuropathy and pain related to shingles. Two other drugs -- the anticonvulsant Neurontin (gabapentin) and the painkiller OxyContin (oxycodone) -- reduced patients' perceptions of neuropathic pain by 33 percent when used in...
Read moreUntil now, opioids have not been considered to be very effective for neuropathic (nerve) pain. They have been a second- or third-line... Read more »
The FDA has analyzed reports of suicidal behavior or ideation from placebo-controlled clinical studies of eleven drugs used to treat... Read more »
There was a recent article in USA Today which cites some interesting statistics about the way Americans treat their depression. I am... Read more »
There is pain in MS. It can be acute or chronic, generally categorized as neuropathic, musculoskeletal, or tertiary. Let's begin looking... Read more »
An estimated 20 million people in the United States suffer from peripheral neuropathy, marked by the degeneration of nerves and in some... Read more »
Source: eOrthopod
Chronic neuropathic pain is mainly treated with medications. These include antidepressants, antiepileptics, opioids, and topical local anaesthetics.... Read more »
A new epilepsy med shows promise for treating several central nervous system conditions. Eslicarbazepine (ESL) fully eliminated seizures in 24... Read more »
One researcher says there are not enough meds available to treat the increasingly common disorder known as neuropathic pain. Wyeth's John A. Butera... Read more »
Dr. Martin Abrahamson at NPR answer questions about diabetes. A listener wants advice on treating diabetic neuropathy, a painful condition caused by... Read more »
The antidepressant Elavil does not treat painful gastrointestinal problems in children, new research suggests, in a finding that contradicts previous... Read more »